Thierry Juhel
Overview
Explore the profile of Thierry Juhel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janho Dit Hreich S, Humbert O, Pace-Loscos T, Schiappa R, Juhel T, Ilie M, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927931
Methods: This ancillary study includes 195 patients with metastatic non-small-cell lung cancer (NSCLC) treated with ICI in monotherapy, either pembrolizumab or nivolumab. Plasmatic levels of IL-18-related compounds, comprising the inhibitor...
2.
Janho Dit Hreich S, Juhel T, Leroy S, Ghinet A, Brau F, Hofman V, et al.
Elife
. 2024 Feb;
12.
PMID: 38300690
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease associated with progressive and irreversible deterioration of respiratory functions that lacks curative therapies. Despite IPF being associated with a dysregulated...
3.
Janho Dit Hreich S, Juhel T, Hofman P, Vouret-Craviari V
Biol Proced Online
. 2023 Jan;
25(1):1.
PMID: 36600200
Background: P2RX7 is a purinergic receptor with pleiotropic activities that is activated by high levels of extracellular ATP that are found in inflamed tissues. P2RX7 has immunomodulatory and anti-tumor proprieties...
4.
Douguet L, Janho Dit Hreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X, et al.
Nat Commun
. 2021 Jan;
12(1):653.
PMID: 33510147
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive...
5.
Benzaquen J, Janho Dit Hreich S, Heeke S, Juhel T, Lalvee S, Bauwens S, et al.
Theranostics
. 2020 Oct;
10(24):10849-10860.
PMID: 33042257
The characterization of new theranostic biomarkers is crucial to improving the clinical outcome of patients with advanced lung cancer. Here, we aimed at characterizing the P2RX7 receptor, a positive modulator...
6.
Hichri M, Vassaux G, Guigonis J, Juhel T, Graslin F, Guglielmi J, et al.
J Clin Med
. 2020 Jan;
9(2).
PMID: 31979418
(1) Background: We recently showed that iodinated contrast media (ICM) reduced thyroid uptake of iodide independently of free iodide through a mechanism different from that of NaI and involving a...
7.
Vassaux G, Zwarthoed C, Signetti L, Guglielmi J, Compin C, Guigonis J, et al.
J Nucl Med
. 2017 Oct;
59(1):121-126.
PMID: 29051343
Perturbation of thyroid iodide uptake is a well-documented side effect of the use of iodinated contrast media (ICM) administered intravenously. This side effect is thought to be mediated by free...
8.
Bozec A, Zangari J, Butori-Pepino M, Ilie M, Lalvee S, Juhel T, et al.
Oncotarget
. 2017 Sep;
8(34):57174-57186.
PMID: 28915663
MicroRNAs (miRs) participate in tumor growth and dissemination by regulating expression of various target genes. MiR-223-3p is suspected of being involved in head and neck squamous cell carcinoma (HNSCC) growth...
9.
Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hebuterne X, et al.
Cancer Res
. 2015 Jan;
75(5):835-45.
PMID: 25564520
Colitis-associated cancer (CAC) is a complication of inflammatory bowel disease (IBD). Binding of extracellular ATP to the purinergic receptor P2RX7 has emerged as a critical event in controlling intestinal inflammation,...